Flortaucipir

DRUG8 trials

Sponsors

Amsterdam UMC, Eli Lilly & Co., Amsterdam UMC Stichting, University of Southern California, Indiana University

Conditions

Alzheimer DiseaseAlzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental DisordersAlzheimer's Disease (AD)Alzheimer's diseaseEarly Mild Cognitive Impairment (EMCI)Early Onset Alzheimer DiseaseHealthy controls (investigating preclinical Alzheimer's Disease)Late Mild Cognitive Impairment (LMCI)

Phase 2

The clinical value of tau PET in the memory clinic (TAP-TAU)

RecruitingCTIS2023-505430-10-00

Amsterdam UMCMild cognitive impairment and dementia

Start: 2024-10-10Target: 360Updated: 2025-04-08

I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

CompletedCTIS2023-507303-55-00

Eli Lilly & Co.Alzheimer Disease

Start: 2020-09-30End: 2025-09-17Target: 224Updated: 2025-01-23

I9X-MC-MTAE: Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer’s Disease

CompletedCTIS2024-512295-36-00

Eli Lilly & Co.Alzheimer Disease

Start: 2021-12-06End: 2025-03-31Target: 55Updated: 2024-11-26

Tau PET imaging in cognitively normal elderly subjects: A twin approach

Not yet recruitingCTIS2024-517634-17-01

Amsterdam UMC StichtingHealthy controls (investigating preclinical Alzheimer's Disease)

Target: 80Updated: 2024-12-02

Synaptic density and tau pathology in Alzheimer’s disease (SYNAPSE)

Not yet recruitingCTIS2024-517636-22-00

Amsterdam UMC StichtingAlzheimer's disease

Target: 30Updated: 2024-12-10

Phase 3

I5T-MC-AACO: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

RecruitingCTIS2025-522340-40-00

Eli Lilly & Co.Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

Start: 2025-12-04Target: 170Updated: 2026-01-19

Unknown Phase

Alzheimer's Disease Neuroimaging Initiative 2

CompletedNCT01231971

University of Southern CaliforniaAlzheimer's Disease (AD), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI) +2

Start: 2011-02-14End: 2017-11-29Updated: 2024-11-21

Longitudinal Early-onset Alzheimer's Disease Study Protocol

RecruitingNCT03507257

Indiana UniversityAlzheimer Disease, Early Onset Alzheimer Disease, Mild Cognitive Impairment

Start: 2018-04-30End: 2026-05-31Target: 850Updated: 2026-02-18

Related Papers

The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study

Alzheimer s Research & Therapy2024-10-194 citations

Self‐reported hearing loss is associated with faster cognitive and functional decline but not diagnostic conversion in the ADNI cohort

Alzheimer s & Dementia2024-09-264 citations

Utility of cerebrovascular imaging biomarkers to detect cerebral amyloidosis

Alzheimer s & Dementia2024-09-011 citations

A protocol paper for the MOTION Study—A longitudinal study in a cohort aged 60 years and older to obtain mechanistic knowledge of the role of the gut microbiome during normal healthy ageing in order to develop strategies that will improve lifelong health and wellbeing

PLoS ONE2022-11-188 citations

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition

Journal of Neurology Neurosurgery & Psychiatry2021-06-2969 citations